This content is PDF only. Please click on the PDF icon to access.
In the early phases of multidrug cancer chemotherapy, the frequency of complete or partial remission was used as the main criterion for the effectiveness and comparative value of any new regimen. When cancer initially responded but recurred rapidly, maintenance of remission with the same or other drugs became a major consideration. As a rule, patients who responded to a particular chemotherapeutic regimen lived longer than those who did not. However, polychemotherapy after recurrence or metastasis of many of the common solid tumors has not significantly altered the overall survival curves. With an inability to statistically increase the survival of patients
Manual of Oncology Therapeutics.. Ann Intern Med. 1982;96:545. doi: https://doi.org/10.7326/0003-4819-96-4-545_3
Download citation file:
Published: Ann Intern Med. 1982;96(4):545.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use